nVerses Capital LLC Makes New Investment in Health Catalyst, Inc. (NASDAQ:HCAT)

nVerses Capital LLC purchased a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 7,300 shares of the company’s stock, valued at approximately $59,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in HCAT. Nisa Investment Advisors LLC boosted its position in Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares during the period. Quarry LP raised its stake in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares during the last quarter. Perfromance Wealth Partners LLC bought a new position in shares of Health Catalyst during the second quarter valued at $64,000. Mackenzie Financial Corp acquired a new position in shares of Health Catalyst during the second quarter worth $70,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Health Catalyst in the first quarter worth $98,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Price Performance

HCAT stock opened at $8.60 on Tuesday. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The stock has a market capitalization of $507.70 million, a PE ratio of -4.65 and a beta of 1.32. The company’s 50-day moving average is $7.76 and its 200-day moving average is $6.96.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The firm had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. During the same quarter last year, the firm posted ($0.21) earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. On average, analysts anticipate that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,396 shares of company stock worth $258,415. Insiders own 2.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on HCAT. Evercore ISI raised their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Piper Sandler lowered their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Stephens lowered their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.58.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.